Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
129 results about "Silencing gene" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Gene silencing: A mechanism by which cells shut down large sections of chromosomal DNA. Gene silencing is done by incorporating the DNA to be silenced into a form of DNA called heterochromatin that is already silent. The process of gene silencing is important for the differentiation of many different types of cells.
Methods and compositions for selecting siRNA of improved functionality
InactiveUS20050255487A1Improve efficiencyGood curative effectOrganic active ingredientsGenetic material ingredientsGene silencingSilencing gene
Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed.
Owner:THERMO FISHER SCIENTIFIC INC
Modified siRNA molecules and uses thereof
ActiveUS20070135372A1Decrease immunostimulatory propertyImmunostimulatory activity of siRNA can be abolishedOrganic active ingredientsSugar derivativesLipid formationLipid particle
The present invention provides chemically modified siRNA molecules and methods of using such siRNA molecules to silence target gene expression. Advantageously, the modified siRNA of the present invention is less immunostimulatory than its corresponding unmodified siRNA sequence and retains RNAi activity against the target sequence. The present invention also provides nucleic acid-lipid particles comprising a modified siRNA, a cationic lipid, and a non-cationic lipid, which can further comprise a conjugated lipid that inhibits aggregation of particles. The present invention further provides methods of silencing gene expression by administering a modified siRNA to a mammalian subject. Methods for identifying and / or modifying an siRNA having immunostimulatory properties are also provided.
Owner:ARBUTUS BIOPHARMA CORPORAT ION
Functional and hyperfunctional siRNA
ActiveUS20050246794A1Improve efficiencyGood curative effectOrganic active ingredientsGenetic material ingredientsSilent geneGene silencing
Owner:THERMO FISHER SCIENTIFIC INC
Lipid encapsulated interfering RNA
ActiveUS20060240093A1Inhibit aggregationMetabolism disorderMicroencapsulation basedLipid formationLipid particle
The present invention provides compositions and methods for silencing gene expression by delivering nucleic acid-lipid particles comprising a siRNA molecule to a cell.
Owner:ARBUTUS BIOPHARMA CORPORAT ION
Lipid encapsulated interfering RNA
InactiveUS20050064595A1Inhibit aggregationMetabolism disorderMicroencapsulation basedLipid formationLipid particle
The present invention provides compositions and methods for silencing gene expression by delivering nucleic acid-lipid particles comprising a siRNA molecule to a cell.
Owner:PROTIVA BIOTHERAPEUTICS
Functional and hyperfunctional siRNA directed against Bcl-2
InactiveUS20050245475A1Improve efficiencyGood curative effectOrganic active ingredientsGenetic material ingredientsSilencing geneCancer research
Owner:THERMO FISHER SCIENTIFIC INC
MODIFIED siRNA MOLECULES AND USES THEREOF
ActiveUS20090270481A1Decrease immunostimulatory propertyImmunostimulatory activity of siRNA can be abolishedOrganic active ingredientsSugar derivativesLipid formationLipid particle
The present invention provides chemically modified siRNA molecules and methods of using such siRNA molecules to silence target gene expression. Advantageously, the modified siRNA of the present invention is less immunostimulatory than its corresponding unmodified siRNA sequence and retains RNAi activity against the target sequence. The present invention also provides nucleic acid-lipid particles comprising a modified siRNA, a cationic lipid, and a non-cationic lipid, which can further comprise a conjugated lipid that inhibits aggregation of particles. The present invention further provides methods of silencing gene expression by administering a modified siRNA to a mammalian subject. Methods for identifying and / or modifying an siRNA having immunostimulatory properties are also provided.
Owner:ARBUTUS BIOPHARMA CORPORAT ION
Double-stranded rna structures and constructs, and methods for generating and using the same
InactiveUS20060035344A1Improve efficiencyPrevent gene silencingAntibody mimetics/scaffoldsMicrobiological testing/measurementNucleic acid sequencingSilencing gene
The present invention relates to novel double-stranded RNA (dsRNA) structures and dsRNA expression constructs, methods for generating them, and methods of utilizing them for silencing genes. Desirably, these methods specifically inhibit the expression of one or more target genes in a cell of animal (e.g., a mammal such as a human) without inducing toxicity. These methods can be used to prevent or treat a disease or infection by silencing a gene associated with the disease or infection. The invention also provides method for identifying nucleic acid sequences that modulate a detectable phenotype, such as the function of a cell, the expression of a gene, or the biological activity of a target polypeptide.
Owner:ALNYLAM PHARM INC
Methods and compositions for DNA mediated gene silencing
ActiveUS7294504B1Peptide/protein ingredientsGenetic material ingredientsSilencing geneGene silencing
Owner:ALLELE BIOTECH & PHARMA
siRNA targeting ribonucleotide reductase M2 polypeptide (RRM2 or RNR-R2)
InactiveUS7592442B2Improve efficiencyGood curative effectOrganic active ingredientsSugar derivativesRibonucleotide Reductase M2 PolypeptideSilencing gene
Owner:THERMO FISHER SCIENTIFIC INC
siRNA targeting inner centromere protein antigens (INCENP)
InactiveUS7582747B2Improve efficiencyGood curative effectSugar derivativesMicrobiological testing/measurementNucleotideGene silencing
Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for INCENP.
Owner:THERMO FISHER SCIENTIFIC INC
Double stranded rna structures and constructs, and methods for generating and using the same
InactiveUS20050239728A1Improve efficiencyPrevent gene silencingSugar derivativesPeptide/protein ingredientsDiseaseSilencing gene
The present invention relates to novel double stranded RNA (dsRNA) structures and dsRNA expression constructs, methods for generating them, and methods of utilizing them for silencing genes. Desirably, these methods specifically inhibit the expression of one or more target genes in a cell or animal (e.g., a mammal such as a human) without inducing toxicity. These methods can be used to prevent or treat a disease or infection by silencing a gene associated with the disease or infection. The invention also provides methods for identifying nucleic acid sequences that modulate a detectable phenotype, such as the function of a cell, the expression of a gene, or the biological activity of a target polypeptide.
Owner:ALNYLAM PHARM INC
siRNA targeting cyclin-dependent kinase inhibitor 1B (p27, Kip1) (CDKN1B)
InactiveUS7612196B2Improve efficiencyGood curative effectOrganic active ingredientsSugar derivativesSilent geneGene silencing
Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for CDKN1B.
Owner:THERMO FISHER SCIENTIFIC INC
siRNA targeting nucleoporin 62kDa (Nup62)
InactiveUS7691998B2Improve efficiencyGood curative effectOrganic active ingredientsSugar derivativesNucleoporinNucleotide
Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for Nup62.
Owner:THERMO FISHER SCIENTIFIC INC
siRNA targeting coatomer protein complex, subunit beta 2 (COPB2)
InactiveUS7619081B2Improve efficiencyGood curative effectSugar derivativesScreening processCoat proteinSilencing gene
Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to COPB2.
Owner:THERMO FISHER SCIENTIFIC INC
siRNA targeting protein kinase N-3 (PKN-3)
ActiveUS7635770B2Improve efficiencyGood curative effectSugar derivativesGenetic material ingredientsProtein targetSilent gene
Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to PKN-3.
Owner:THERMO FISHER SCIENTIFIC INC
Methods and compositions for gene silencing
InactiveUS20070130653A1Sugar derivativesOther foreign material introduction processesDevelopmental stageHeterologous
Methods and compositions are provided for reducing the level of expression of a target polynucleotide in an organism. The methods and compositions selectively silence the target polynucleotide through the expression of a chimeric polynucleotide comprising the target for a sRNA (the trigger sequence) operably linked to a sequence corresponding to all or part of the gene or genes to be silenced. In this manner, the final target of silencing is an endogenous gene in the organism in which the chimeric polynucleotide is expressed. In a further embodiment, the miRNA target is that of a heterologous miRNA or siRNA, the latter of which is coexpressed in the cells at the appropriate developmental stage to provide silencing of the final target when and where desired. In a further embodiment, the final target may be a gene in a second organism, such as a plant pest, that feeds upon the organism containing the chimeric gene or genes. Compositions further comprise vectors, seeds, grain, cells, and organisms, including plants and plant cells, comprising the chimeric polynucleotide of the invention.
Owner:PIONEER HI BRED INT INC +1
Compositions and methods for silencing gene expression
InactiveUS20130318657A1Climate change adaptationOther foreign material introduction processesBiotechnologySilencing gene
Owner:MONSANTO TECH LLC
siRNA targeting tumor protein 53 (p53)
InactiveUS7781575B2Improve efficiencyGood curative effectSugar derivativesCarbohydrate active ingredientsSilencing geneGene silencing
Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed.
Owner:THERMO FISHER SCIENTIFIC INC
Genomic screen for epigenetically silenced genes associated with cancer
InactiveUS7794929B2Easy to detectRestoring expressionOrganic active ingredientsBioreactor/fermenter combinationsCancer cellSilencing gene
Owner:THE JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE
Compositions and methods for silencing genes expressed in cancer
The present invention provides therapeutic nucleic acids such as interfering RNA (e.g., siRNA) that target the expression of genes associated with tumorigenesis and / or cell transformation, lipid particles (e.g., nucleic acid-lipid particles) comprising one or more (e.g., a cocktail) of the therapeutic nucleic acids, methods of making the lipid particles, and methods of delivering and / or administering the lipid particles, e.g., for the treatment of a cell proliferative disorder such as cancer.
Owner:US DEPT OF HEALTH & HUMAN SERVICES +1
Methylation markers for diagnosis and treatment of ovarian cancer
InactiveUS20070087365A1Reducing and inhibiting neoplastic growthRestoring expression of the polypeptide in the cellMicrobiological testing/measurementMaterial analysisTumour suppressor geneSilencing gene
Twenty-three markers are provided which are epigenetically silenced in ovarian cancers. The markers can be used diagnostically, prognostically, therapeutically, and for selecting treatments that are well tailored for an individual patient. Restoration of expression of silenced genes can be useful therapeutically, for example, if the silenced gene is a tumor-suppressor gene. Restoration can be accomplished by supplying non-methylated copies of the silenced genes or polynucleotides encoding their encoded products. Alternatively, restoration can be accomplished using chemical demethylating agents or methylation inhibitors. Kits for testing for epigenetic silencing can be used in the context of diagnostics, prognostics, or for selecting “personalized medicine” treatments.
Owner:MDXHEALTH
Triggered covalent probes for imaging and silencing genetic expression
ActiveUS20110288148A1Reducing and eliminating expression of geneReduction in expression of target geneAntibacterial agentsOrganic active ingredientsCross linkerSilencing gene
The present invention relates to the use of cross-linking probes to covalently bind probes to nucleic acid targets. In some embodiments, the probe comprises an initiator region that is able to bind to a first portion of a target nucleic acid, a probe region linked too the initiator region that is able to bind to a second region of the target nucleic acid and that comprises one or more cross-linkers, and a blocking region hybridized to the probe region.
Owner:CALIFORNIA INST OF TECH
siRNA targeting v-myc myelocytomatosis viral oncogene homolog (MYC)
InactiveUS7951935B2Improve efficiencyGood curative effectSugar derivativesActivity regulationViral OncogeneSilent gene
Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to MYC.
Owner:THERMO FISHER SCIENTIFIC INC
Triggered covalent probes for imaging and silencing genetic expression
ActiveUS8658780B2Reducing its translationReducing and eliminating expression of geneAntibacterial agentsSugar derivativesCross linkerSilencing gene
The present invention relates to the use of cross-linking probes to covalently bind probes to nucleic acid targets. In some embodiments, the probe comprises an initiator region that is able to bind to a first portion of a target nucleic acid, a probe region linked too the initiator region that is able to bind to a second region of the target nucleic acid and that comprises one or more cross-linkers, and a blocking region hybridized to the probe region.
Owner:CALIFORNIA INST OF TECH
siRNA Targeting TNFalpha
ActiveUS20090306356A1Improve efficiencyGood curative effectOrganic active ingredientsSugar derivativesSilencing geneGene silencing
Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to TNFα.
Owner:THERMO FISHER SCIENTIFIC INC
Methods and compositions for selecting siRNA of improved functionality
ActiveUS9228186B2Improve efficiencyGood curative effectOrganic active ingredientsSugar derivativesNucleotideGene silencing
Owner:THERMO FISHER SCIENTIFIC INC
Methylation markers for diagnosis and treatment of ovarian cancer
InactiveUS7507536B2Reducing and inhibiting neoplastic growthRestoring expression of the polypeptide in the cellMicrobiological testing/measurementMaterial analysisSilencing genePolynucleotide
Owner:MDXHEALTH
Methods and compositions for use in preparing siRNAs
Methods and compositions for producing siRNAs, e.g., in the form of a d-siRNA composition, from dsRNAs are provided. In the subject methods, a dsRNA is contacted with a composition that includes an activity that cleaves dsRNA into siRNAs, where the composition efficiently cleaves dsRNA into siRNAs. siRNAs produced by the subject methods find use in a variety of applications, particularly in applications where the specific reduction or silencing of a gene is desired. Also provided are kits for use in practicing the subject invention.
Owner:THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV
siRNA targeting serine/threonine protein kinase AKT
InactiveUS20080161547A1Improve efficiencyGood curative effectSugar derivativesScreening processThreonineSilencing gene
Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to an AKT protein.
Owner:DHARMACON INC
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com